Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer

被引：88
|
作者：
Freimund, Alison E. [1 ,2 ]
Beach, Jessica A. [1 ]
Christie, Elizabeth L. [1 ,2 ]
Bowtell, David D. L. [1 ,2 ]
机构：
[1] Peter MacCallum Canc Ctr, Canc Res Div, 305 Grattan St, Melbourne, Vic 3000, Australia
[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic 3010, Australia
来源：
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2018年 / 32卷 / 06期
关键词：
Ovarian cancer; Primary resistance; Acquired resistance; Chemotherapy; Drug resistance mechanisms; HOMOLOGOUS RECOMBINATION; PARP INHIBITORS; PHASE-II; MULTIDRUG-RESISTANCE; GENE AMPLIFICATION; CELL CARCINOMA; POOR SURVIVAL; PLATINUM; CHEMOTHERAPY; EXPRESSION;
D O I：
10.1016/j.hoc.2018.07.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Resistance in ovarian cancer is driven by a range of mechanisms, some of which are therapy specific whereas others confer multidrug resistance. This review outlines our current understanding of the heterogeneous mechanisms of both primary and acquired drug resistance in high-grade serous ovarian cancer with a focus on the most common therapeutics, including platinum and taxanes. Current therapeutic strategies for overcoming resistance, including the use of non-P-glycoprotein substrate therapies, are outlined, with an emphasis on the importance of developing resistance biomarkers to guide future therapy approaches and improve patient outcomes.
引用
收藏
页码：983 / +
页数：15
相关论文
共 50 条
  • [1] Drug resistance in end-stage high-grade serous ovarian cancer.
    Christie, Elizabeth L.
    Alsop, Kathryn
    Au-Yeung, George
    Pandey, Ahwan
    Bowtell, David D. L.
    [J]. CLINICAL CANCER RESEARCH, 2020, 26 (13) : 17 - 17
  • [2] Determinants of resistance and response in high-grade serous ovarian cancer
    Bowtell, David D. L.
    [J]. CLINICAL CANCER RESEARCH, 2016, 22
  • [3] Evolution of platinum resistance in high-grade serous ovarian cancer
    Cooke, Susanna L.
    Brenton, James D.
    [J]. LANCET ONCOLOGY, 2011, 12 (12): : 1169 - 1174
  • [4] Unveiling the epigenomic mechanisms of acquired platinum-resistance in high-grade serous ovarian cancer
    Silva, Romina
    Glennon, Kate
    Metoudi, Michael
    Moran, Bruce
    Salta, Sofia
    Slattery, Karen
    Treacy, Ann
    Martin, Terri
    Shaw, Jacqui
    Doran, Peter
    Lynch, Lydia
    Jeronimo, Carmen
    Perry, Antoinette S.
    Brennan, Donal J.
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (01) : 120 - 132
  • [5] INVESTIGATING EPIGENOMIC INVOLVEMENT IN ACQUIRED DRUG-RESISTANCE IN HIGH-GRADE SEROUS OVARIAN CANCER
    Silva, R.
    Metoudi, M.
    Glennon, K.
    Perry, A.
    Brennan, D.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A335 - A335
  • [6] Heterogeneous mechanisms of acquired resistance in high grade serous ovarian cancer
    Bowtell, David D. L.
    [J]. CANCER RESEARCH, 2015, 75
  • [7] Epigenetic Mechanisms and Therapeutic Targets in Chemoresistant High-Grade Serous Ovarian Cancer
    Matthews, Bayley G.
    Bowden, Nikola A.
    Wong-Brown, Michelle W.
    [J]. CANCERS, 2021, 13 (23)
  • [8] Screening of drug candidates to repurpose for high-grade serous ovarian cancer treatment
    Bay, Marie L.
    Skorda, Aikaterini
    Rasmussen, Benita S.
    Arias, Jaume R.
    Lauridsen, Anna R.
    Huhtinen, Kaisa
    Hautaniemi, Sampsa
    Hynninen, Johanna
    Kallunki, Tuula
    [J]. CANCER RESEARCH, 2024, 84 (05)
  • [9] Acquired chemotherapy resistance in high-grade serous ovarian cancer patients.
    Christie, Elizabeth L.
    Beach, Jessica
    Etemadmoghadam, Dariush
    Garsed, Dale
    Patch, Ann-Marie
    Fereday, Sian
    Pattnaik, Swetansu
    Brady, Samuel
    Bild, Andrea
    Bowtell, David D. L.
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (15) : 20 - 20
  • [10] The Changing View of High-Grade Serous Ovarian Cancer
    Berns, Els M. J. J.
    Bowtell, David D.
    [J]. CANCER RESEARCH, 2012, 72 (11) : 2701 - 2704
12345